Le Lézard
Classified in: Ebola virus, Health
Subject: WOM

Important Information on MARVELON® 28 (desogestrel/ethinyl estradiol) Oral Contraceptive Tablets - Absence of Day-of-the-week Label Stickers



KIRKLAND, QC, Sept. 11, 2018 /CNW Telbec/ - Merck Canada Inc., known as MSD outside Canada and the United States, notified health care professionals of important information on MARVELON® 28 (desogestrel/ethinyl estradiol) Oral Contraceptive Tablets. The letter stated that some lots of MARVELON® 28 distributed in Canada do not contain day-of-the-week label stickers (see picture below).  

Day-of-the-week Label Stickers (CNW Group/Merck Canada Inc.)

The day-of-the-week label is a sticker that can be applied on the blister pack, indicating the first day of the week when the medication is started. It may help the patient track the tablet intake.  The absence of these stickers may increase the risk of non-adherence to the schedule and taking an incorrect number of tablets. Non-adherence to daily oral contraceptive tablet intake can increase the risk of pregnancy. Please note that this issue does not impact the efficacy or safety of the tablet itself if taken as prescribed.

We apologize for this situation and we are working on correcting this issue in a timely manner. In the meantime, we are not distributing MARVELON® 28 until we can start once again delivering product that contain the day-of-the-week label stickers.

Merck Canada Inc. recommends to health care professionals to proactively mention the absence of day-of-the-week label stickers to their patients when prescribing or dispensing MARVELON® 28.  Furthermore, patients can be counseled to use a calendar to track the tablet intake.

As of September 10, Merck Canada Inc. will be delivering day-of-the-week label stickers to Canadian retail pharmacies who carry the product in their dispensary as well as clinics which received MARVELON® 28 samples.

We understand that generic alternatives to MARVELON® 28 are also available and do contain day-of-the-week label stickers. We would also like to underline that MARVELON® 21 is not affected by this situation.

Health care professionals or patients do not need to return the MARVELON® 28 products currently on the market, since this issue does not impact the efficacy or safety of the tablet itself if taken as prescribed.

For any questions, patients are instructed to talk to their health care professional.

About MARVELON® (desogestrel/ethinyl estradiol)
To consult the Canadian product monograph for complete prescribing information including contraindications, warnings, precautions, adverse reactions, interactions, dosing and condition of clinical use, please click here.1

About Merck
For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

® Merck Sharp & Dohme B.V. Used under license.

 

Reference:

  1. MARVELON® 28 (desogestrel/ethinyl estradiol) Product Monograph. Merck Canada Inc. Available at: http://www.merck.ca/static/pdf/MARVELON-PM_E.pdf

 

SOURCE Merck Canada Inc.


These press releases may also interest you

at 09:00
Technological innovations, increase in disposable income across developing regions, and rise in internet marketing are expected to drive the global baby diapers industry.   Allied Market Research published a report, titled, Baby Diapers Market by...

20 sep 2018
Merck , known as MSD outside the United States and Canada, today issued its 2017/2018 global Corporate Responsibility Report. The report reflects the company's performance and progress in its four corporate responsibility priority areas of Access to...

19 sep 2018
The "Heterogeneous Networks (HetNets) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. This report analyzes the worldwide markets for Heterogeneous Networks (HetNets) in US$ Million for major Geographic...

19 sep 2018
The "Dental Infection Control Products - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin...

18 sep 2018
The "Global Anti-infective Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering. The global...

18 sep 2018
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the National Cancer Institute (NCI) has awarded the Company a government grant (number 1R43CA232977-01). The title...




News published on 11 september 2018 at 12:04 and distributed by: